Drug Profile
DB 055
Alternative Names: CM 352Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Digna Biotech
- Class Small molecules
- Mechanism of Action Fibrinolysis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemorrhage
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Haemorrhage in Spain (IV)
- 21 Jan 2016 Preclinical trials in Haemorrhage in Spain (IV)